Cetuximab Injection
Cetuximab injection is a targeted cancer treatment used for certain types of head and neck cancer and colorectal cancer.
🧬 Where this information comes from Click to expand
The clinical label records used on this page are FDA-filed Structured Product Labeling (SPL) retrieved through openFDA. We identified 1 clinical label set within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. Forms, routes, brands, labelers, strengths, and NDC product-record counts are built separately from matching FDA National Drug Code Directory records. The linked DailyMed document is a representative official source for verification, not the page’s only clinical source. View the linked label on DailyMed →
⚠️ FDA Boxed Warning — the FDA’s strongest safety alert ▾
Erbitux carries two serious black box warnings from the FDA.
Infusion reactions: Erbitux can cause severe and potentially fatal reactions during or after the IV infusion — including sudden trouble breathing, low blood pressure, shock, and cardiac arrest. These can happen even when allergy medicine is given beforehand. If a serious reaction occurs, the infusion must be stopped immediately and permanently.
Cardiopulmonary arrest (heart and breathing stopping): Sudden death occurred in some head and neck cancer patients receiving Erbitux with radiation therapy or with platinum-based chemotherapy. Blood electrolyte levels — including magnesium, potassium, and calcium — must be checked regularly during and after treatment, because imbalances can trigger dangerous heart events.
📖 Cetuximab Injection: Patient Information Guide
A plain-language walkthrough of Cetuximab Injection — what it treats, how it works, how it’s taken, side effects, warnings and interactions. Tap any section to expand it.
🎯What it's used for▾
Cetuximab injection (Erbitux) is a targeted therapy approved for specific types of head and neck cancer and colorectal cancer.
- Erbitux treats locally or regionally advanced squamous cell carcinoma of the head and neck — given together with radiation therapy
- Erbitux treats recurrent or metastatic squamous cell carcinoma of the head and neck — given with platinum-based therapy plus fluorouracil as first-line treatment
- Erbitux treats recurrent or metastatic squamous cell carcinoma of the head and neck as a single agent when prior platinum-based therapy has failed
- Erbitux treats K-Ras wild-type, EGFR-expressing metastatic colorectal cancer — in combination with FOLFIRI (first-line), with irinotecan (in irinotecan-refractory patients), or as a single agent after other chemotherapy has failed
- Erbitux treats BRAF V600E mutation-positive metastatic colorectal cancer — in combination with encorafenib, after prior therapy, in adults
- Erbitux is not indicated for Ras-mutant colorectal cancer or when Ras mutation test results are unknown
⚙️How it works▾
Cetuximab is a monoclonal antibody — a lab-made protein that acts like a guided missile — that locks onto EGFR (epidermal growth factor receptor), a protein found on the surface of many cancer cells. By blocking EGFR, cetuximab cuts off signals that tell cancer cells to grow and divide, promotes cancer cell death (apoptosis), and reduces the tumor's ability to build new blood vessels. It may also help the immune system attack tumor cells directly through a process called antibody-dependent cellular cytotoxicity (ADCC).
In colorectal cancer with a BRAF V600E mutation, cancer cells can activate growth signals through a separate pathway even when EGFR is blocked — making BRAF inhibitors alone less effective. Combining cetuximab with encorafenib (a BRAF inhibitor) blocks both pathways at once, overcoming this resistance.
💊How it's taken▾
Erbitux is given as a slow intravenous (IV) infusion in a clinic or infusion center — never at home or as a quick injection. Depending on the treatment plan, infusions may be given once a week or once every two weeks. Before the first infusion (and before later infusions if needed), an antihistamine is given to reduce the risk of a reaction. When given alongside chemotherapy or radiation, Erbitux is completed at least 1 hour before those treatments begin.
- Weekly schedule: a longer first infusion, then shorter infusions each week after
- Every-two-week schedule: the same infusion length each time
- Treatment continues until the cancer progresses or side effects become unacceptable
🤒Side effects — in detail▾
The most common side effects with Erbitux — whether used alone, with radiation, or with chemotherapy — include:
- Skin rash (often acne-like), itching, and nail changes
- Headache
- Diarrhea
- Infection
- Fatigue
- Nausea and abdominal pain
- Decreased appetite
- Joint pain (arthralgia) — especially when used with encorafenib
Serious reactions to watch for include severe infusion reactions (trouble breathing, chest pain, sudden dizziness), signs of lung inflammation (new or worsening shortness of breath or cough), severe skin reactions or infections, and muscle cramps or weakness that may signal low magnesium or other electrolyte problems — contact your care team right away if any of these occur.
⚠️Warnings & precautions▾
- Infusion reactions: Can be severe and fatal. Most happen during the first infusion. Signs include sudden breathing difficulty, throat tightness, low blood pressure, or chest pain. Emergency treatment must be immediately available during every infusion.
- Cardiopulmonary arrest: Sudden cardiac arrest and death have occurred in head and neck cancer patients receiving Erbitux with radiation or platinum-based chemotherapy. Patients with a history of heart disease, heart failure, or arrhythmia are at higher risk.
- Electrolyte monitoring: Low magnesium, potassium, and calcium levels can develop and trigger serious heart events. Blood levels must be checked during and for at least 8 weeks after treatment ends.
- Lung toxicity: Interstitial lung disease (lung inflammation) has occurred, including one fatal case. New or worsening breathing symptoms need prompt evaluation.
- Skin reactions: Severe acne-like rashes, mucocutaneous reactions, and related infections can occur. Limit sun exposure during treatment.
- Fetal harm: Erbitux can cause miscarriage or fetal harm. Pregnancy must be ruled out before starting, and effective contraception used during treatment and for 2 months after the last dose.
- Colorectal cancer patient selection: Erbitux is harmful — not beneficial — in patients with Ras-mutant metastatic colorectal cancer. FDA-approved genetic testing is required before use.
🔀What it interacts with▾
Based on pharmacokinetic studies conducted for Erbitux, no clinically significant drug interactions were identified with the following agents:
- Irinotecan — no effect on cetuximab or irinotecan levels when used together
- Cisplatin — no pharmacokinetic interaction observed
- Carboplatin — no pharmacokinetic interaction observed
- Encorafenib — no clinically significant change in the levels of either drug when combined with Erbitux
This is not a complete list of interactions. Always talk with your doctor or pharmacist before starting, stopping, or changing any medication.
📋Before taking it▾
- Tell your doctor if you have a history of coronary artery disease, congestive heart failure, or irregular heart rhythms — the risk of sudden cardiac death may be higher when Erbitux is used with radiation or certain chemotherapy drugs
- Tell your doctor about any history of tick bites or red meat allergy — this may indicate alpha-gal antibodies, which can increase the risk of severe infusion reactions; testing may be considered before starting Erbitux
- Pregnancy: Erbitux can cause fetal harm or pregnancy loss — tell your doctor immediately if you are pregnant or become pregnant; a pregnancy test is required before starting treatment
- Contraception: Women who can become pregnant must use effective birth control during treatment and for 2 months after the last dose; Erbitux may also impair fertility in women
- Breastfeeding: Do not breastfeed during treatment or for 2 months after the last dose due to potential risk to the infant
- Children: Safety and effectiveness in pediatric patients have not been established
- Older adults: In colorectal cancer studies, patients aged 65 and older showed no overall difference in safety or effectiveness; head and neck cancer studies did not include enough older patients to draw firm conclusions
- Colorectal cancer patients must have Ras and BRAF mutation testing using an FDA-approved test before starting Erbitux
📡Pharmacodynamics — effects in the body▾
Cetuximab binds to EGFR on both normal and tumor cells, blocking the growth signals that cancer cells rely on. This leads to slowed cell growth, promotion of programmed cell death (apoptosis), and reduced production of proteins that help tumors grow new blood vessels. In lab and animal studies, cetuximab enhanced the anti-tumor effects of both radiation therapy and chemotherapy. No anti-tumor effect was seen in tumors that did not express EGFR.
🔬Pharmacokinetics — how your body processes it▾
Erbitux is given intravenously and stays mostly within the bloodstream, with a distribution volume similar to the body's vascular space. It follows nonlinear pharmacokinetics — meaning that as the dose increases, the drug is cleared from the body more slowly and blood levels rise more than proportionally. After starting treatment on the standard weekly schedule, steady blood levels are typically reached by the third weekly infusion. The average half-life (time for the body to clear half the drug) is about 112 hours — roughly 4.5 days — though this can vary widely. Age, sex, race, and kidney or liver function do not significantly affect how the body handles cetuximab.
📦How to store it▾
Store vials under refrigeration at 2° C to 8° C (36° F to 46° F). Do not freeze or shake.
📄 Written from Cetuximab Injection’s FDA-approved label information, summarized in plain language with AI, and reviewed by our pharmacy team before publication. Every point is grounded in that labeling — nothing is invented. How we use AI →
Supplements & herbs that interact with Cetuximab Injection
17 supplements and herbal products have documented interactions with Cetuximab Injection in the licensed clinical database we use. Most are manageable — but your pharmacist should know about everything you take, including vitamins and herbals.
- Major · 1
- Moderate · 7
- Minor · 9
Educational information from a licensed clinical database (Natural Medicines) — see our data sources & update cadence. Not medical advice: an interaction being documented does not mean it will happen to you; do not start or stop medications or supplements without professional guidance.
Nutrient depletion considerations
Cetuximab Injection has been associated with lower levels of 1 nutrient in the clinical literature. This does not mean a deficiency will occur — it means these may be worth discussing with your pharmacist or healthcare provider, especially with long-term use.
Educational information from a licensed clinical database (Natural Medicines) — not medical advice. Do not start or stop medications or supplements without professional guidance.
🩺 Pharmacist Counseling Corner
Quick, plain-English answers to the questions patients ask most about Cetuximab Injection — the kind of thing our pharmacy team would talk through with you at the counter.
What exactly does Erbitux do — is it a chemotherapy drug? ▾
What should I watch for during and after my infusion? ▾
I heard there's a risk of heart problems. Should I be worried? ▾
Why do I need a blood test to check my magnesium levels? ▾
Will I get a rash? What should I do about it? ▾
Is it safe to get pregnant or breastfeed while on Erbitux? ▾
Is Cetuximab Injection available over the counter? ▾
When was Cetuximab Injection first available? ▾
Who makes Cetuximab Injection? ▾
💬 Answers drafted from Cetuximab Injection’s FDA-approved label information, summarized in plain language with AI, and reviewed by our pharmacy team before publication. Grounded in that labeling — nothing is made up. How we use AI →
🧰 Keep exploring
💊 How Cetuximab Injection comes
Cetuximab Injection is available in 1 form. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.
Injection
How this form is used
- Erbitux is used intravenously for locally or regionally advanced squamous cell carcinoma of the head and neck, combined with radiation therapy
- Erbitux is used intravenously for recurrent or metastatic squamous cell carcinoma of the head and neck, with platinum-based therapy plus fluorouracil, or alone after prior platinum-based therapy
- Erbitux is used intravenously for K-Ras wild-type, EGFR-expressing metastatic colorectal cancer, with FOLFIRI, with irinotecan, or as a single agent
- Erbitux is used intravenously for BRAF V600E mutation-positive metastatic colorectal cancer in combination with encorafenib, after prior therapy
- Erbitux is administered only by intravenous infusion — never as a rapid push or bolus injection
- Erbitux is given on a weekly or every-two-week schedule depending on the treatment plan; an antihistamine must be given 30–60 minutes before each infusion
- Erbitux infusions must be administered through a low protein-binding 0.22-micrometer in-line filter using an infusion pump or syringe pump
- Patients must be monitored for at least 1 hour after each Erbitux infusion in a setting equipped to treat severe allergic reactions
📊 Cetuximab Injection across the U.S. market
How Cetuximab Injection appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.
Share of FDA-listed product records by manufacturer — FDA National Drug Code Directory. Record counts are not sales or prescription volume.
📈 How widely Cetuximab Injection is used
A general measure of how commonly Cetuximab Injection is prescribed, based on Medicaid — one of the largest public drug programs. The figure below is prescriptions filled in Q1–Q4 2025, summed across every form and brand of the drug.
Think of this as a proxy for how widely Cetuximab Injection is used, drawn from freely available public data. Medicaid is just one program — these numbers don’t include Medicare, other government coverage, or commercial and cash-pay prescriptions, so real-world use is higher than what’s shown here.
How commonly is Cetuximab Injection prescribed? Of the 1,596 medications we measure, Cetuximab Injection ranks #955 by Medicaid prescriptions — more than 40% of them.
Utilization by Cetuximab Injection product
Pick a product to see its own Medicaid numbers. Each chip is one clinical product — a specific strength & dosage form as defined by RxNorm — with brand-name and generic versions combined.
100 ML cetuximab 2 MG/ML Injection Most dispensed
Summed across the 1 of 1 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1657663
50 ML cetuximab 2 MG/ML Injection
Summed across the 1 of 1 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1657658
Shares are of the Medicaid prescriptions shown here. Product grouping follows RxNorm (the National Library of Medicine’s drug terminology), so “one product” means one strength & dosage form regardless of manufacturer. Dollar figures are gross Medicaid reimbursement before mandatory rebates — rebates (often large, especially for brand-name drugs) are confidential, so actual net cost to Medicaid is lower than shown.
Source: Medicaid State Drug Utilization Data (CMS), aggregated by generic ingredient — summed across every NDC (all brands, strengths, salt forms and dosage forms) of Cetuximab Injection, and across all states and both fee-for-service and managed-care claims. A general popularity signal; it excludes Medicare, commercial insurance and cash prescriptions, so it is not total U.S. use. Based on the 2 of 2 listed Cetuximab Injection NDCs with Medicaid activity.
🔍 Compare Cetuximab Injection products
A representative set of FDA-listed product records for Cetuximab Injection — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)
| Strength | Route | Manufacturer / Labeler | Category ⓘ | Details |
|---|---|---|---|---|
| 💊Injection | ||||
| 2 mg/mL | Intravenous | ImClone LLC × 6 listings | BLA | View NDC → |
| 1 kg/kg | — | Merck Serono Sa | BULK INGREDIENT | View NDC → |
Showing 7 of 7 products — FDA National Drug Code Directory. See every product, package size and price: browse all 7 Cetuximab Injection NDCs →
📈 What people report — real-world data (FDA FAERS)
After a medicine reaches the market, patients, doctors and drugmakers can send the FDA reports of problems they think may be linked to it. Here’s what’s been reported for Cetuximab Injection — a signal of what to watch for, not proof the drug caused it.
Source: openFDA, from the FDA Adverse Event Reporting System (FAERS). These are voluntary reports — they don’t prove the drug caused the effect, and counts reflect how often something was reported, not how often it actually happens. Reports also often name the very problem the medicine is taken for — a common reason to file one is that the drug didn’t help — so for a pain reliever you may see “pain” high on the list; that points to why the report was filed, not to the drug causing the symptom. This counts every report that lists Cetuximab Injection in any role, so the total runs higher than the FDA’s official dashboard, which counts only cases where the drug is the suspect. For the authoritative figures, see the FDA FAERS Public Dashboard. Always talk to your pharmacist or doctor.
🏛️ The road to your pharmacy
How Cetuximab Injection went from FDA review to the pharmacy shelf — the key milestones in its regulatory journey.
Source: Drugs@FDA.
🚨 Recall history
A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.
Source: openFDA drug enforcement (recall) reports.
RxNorm Concept Web — From Ingredient to Every Form and Strength
This page starts with one ingredient concept (IN). The branches below show its dose-form concepts (SCDF), then the available clinical drug and strength concepts (SCD). Combination products remain separate concepts with their own pages.
RxCUI 318341 1 dose form · 2 strengths
-
Dose form (SCDF) Injection RxCUI 1657657In current FDA listingsClinical drug / strength (SCD) 50 ML cetuximab 2 MG/MLRxCUI 1657658100 ML cetuximab 2 MG/MLRxCUI 1657663
Look up RxCUI 318341 in the RxCUI Atlas →
RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.
📦 Supply & shortage status
Whether Cetuximab Injection is in short supply in the U.S. right now, plus any shortage history the FDA has on record. A shortage usually reflects a manufacturing or demand issue — not a safety problem with the drug.
Source: openFDA, from the FDA Drug Shortages database.
🏷️ Sold under these brand names
🏭 Manufacturers & labelers
RxNorm drug class
Cetuximab Injection belongs to the Epidermal Growth Factor Receptor Antagonist class.
Classified by RxNorm RxClass — the U.S. National Library of Medicine's standardized drug-classification service (Established Pharmacologic Class from the FDA, the ATC drug family from the WHO, and mechanism of action). Reference only, not medical advice.
🔬 Where this comes from
Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.
How we combine label and product data
HelloPharmacist combines public FDA and NLM records; we don’t author the underlying clinical facts. We identified 1 FDA-filed SPL label set within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. The representative label is the starting point for the displayed reference monograph; the 12 largest stored in-scope SPL records, which may include that representative, are compared section by section, and the longest available version of each section is retained. Forms, routes, brands, labelers, product-listed strengths, and product-record counts are aggregated separately from ingredient-matched FDA NDC Directory records; package records listed above are associated with the linked SPL; and the normalized concept hierarchy comes from NLM RxNorm.
Where a section is identified as AI-written, its plain-language text is generated from bounded label evidence. New draft drug pages remain in the admin review queue before first publication. ImClone LLC is the representative DailyMed label linked for verification and dates; it is not the sole source used for the page.
This is general education, not medical advice — always consult your doctor or pharmacist about your medications and any medical condition. For the exact wording of the linked representative label, view that label on DailyMed; some displayed composite sections may come from other in-scope SPL labels. Learn how we use AI and our data sources & update cadence.